MTND4LP12

Across TCGA pan-cancer cohorts, MTND4LP12 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MTND4LP12 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MTND4LP12 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND4LP12 expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.

LUAD, ESCA, and PRAD are the cancer types where MTND4LP12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.245	0.835	<.001	45	view →
ESCA	OS	Tertile	All	0.201	0.951	<.001	36	view →
PRAD	DFS	Tertile	All	0.120	0.935	<.001	18	view →
PCPG	DFS	Tertile	All	0.063	0.924	<.001	18	view →
SARC	OS	Tertile	All	0.143	0.745	<.001	18	view →
GBM	DFS	Tertile	All	0.073	0.244	.021	9	view →
BLCA	DFS	Tertile	IV	0.064	0.476	<.001	9	view →
LIHC	DFS	Tertile	III,IV	1.000	0.169	.044	9	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTND4LP12–LUAD (OS)

Open the LUAD breakdown →